Source-Omega Taps Large Oil Supply Offers First Self-Affirmed GRAS Schizochytrium Oil Generic API

Chapel Hill, NC, March 08, 2012 --(PR.com)-- In a March 6 interview with Cambridge students in the Masters in Bioscience Enterprise Program, the University of Cambridge, Department of Chemical Engineering and Biotechnology, Source-Omega Founder and CEO Dr Scott Doughman revealed challenges and opportunities he sees in the algae oil omega-3 industry.

“The real problems have been a lack of competitive pricing and a lack of dual supply security in the US marketplace,” said Dr Doughman in the interview.

Source-Omega’s CEO indicated further that he did not expect how large the new oil supply actually is already.

“We have tested the oil and certified it to our highest quality expectations. I give it a green light for supplements, as a generic Rx API, as a powder for food and soon even for Novel Food status and use in infant formula,” said Doughman.

For context, Lipitor’s recent off patent status was met with generics ready to market. With algae oil DHA going off patent Source-Omega claims to have identified both a vacuum of readiness by US producers and only one new reliable and substantiated Schizochytrium DHA supply, with others soon to enter over the next two years. The Source-Omega launch is planned for Easter 2012.

###